-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: U

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Uaprasert, N.
2081 - An Effective Screening Algorithm and a Simple DNA Sequencing Protocol for Molecular Characterization of Rare Alpha-Globin Variants
3256 - Low Pre-Test Probability Scores Are Not Sufficient to Exclude Heparin-Induced Thrombocytopenia in Critically Ill Patients
Ubels, J.
2970 - The Combination of SKY92 and ISS Provides a Powerful Tool to Identify Both High Risk and Low Risk Multiple Myeloma Cases, Validation in Two Independent Cohorts
Uberti, J. P.
1902 - A Pilot Study of Peripheral Blood Hematopoietic Stem Cells Mobilization with the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
3228 - Encouraging Outcomes in African-American Patients with Use of Post-Transplant Cyclophosphamide after HLA Mismatched Hematopoietic Stem Cell Transplant
Ubidia, D.
4492 - Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
Uchida, N.
1150 - More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells
Uchida, N.
154 - The Impact of Donor Age on Outcome after Unrelated Bone Marrow Transplantation: Comparison with Unrelated Cord Blood Transplantation
1905 - Umbilical Cord Blood Is the Most Significant Risk Factor for the Development of Bloodstream Infection after Allogeneic Hematopoietic Cell Transplantation
3206 - Impact of Unbalanced Translocation Der(1;7)(q10;p10) and -7/Del(7q) on the Prognostic Value after Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Nationwide Retrospective Study
4371 - Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation
Uchida, T.
2714 - Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
2724 - Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma
2868 - A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)
Uchimaru, K.
572 - Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population
Uchino, Y.
3940 - Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy
Uchiyama, H.
3877 - The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
Uckelmann, H.
2391 - Stem Cell-like Megakaryocyte Progenitors As Driving Forces of IFN-Induced Emergency Megakaryopooesis
Uda, K.
1353 - Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations
Udani, R. A.
758 - Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program
1053 - Genetic Evaluation in aHUS: Characterization of a Variant of Unknown Significance in CFHR3
Udd, K. A.
1778 - Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenström's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels
2931 - Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia
Ueda, A.
1800 - Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs
Ueda, K.
482 - Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms
Ueda, K.
3700 - Prediction of the Lenalidomide Toxicity and Its Therapeutic Efficacy in Japanese Multiple Myeloma Patients By Measuring Its Plasma Concentration.
Ueda, K.
1507 - R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL
Ueda, M.
1360 - Glycogen Synthase Kinase-3 (GSK3) Inhibition with Lithium in Combination with Tretinoin Induces Differentiation in Non-Promyelocytic Acute Myeloid Leukemia (AML)
Ueda, N.
3424 - Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation
Ueda, T.
3023 - YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin
Ueda, Y.
2868 - A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)
Ueda, Y.
2138 - Coversin Blocked in Vitro Hemolysis in an Eculizumab-Resistant PNH Patient with the C5 Polymorphism (c.2654G>A)
Ueda, Y.
2715 - Outcome of Gastric Diffuse Large B-Cell Lymphoma and Usefulness of PET-CT in Detecting Gastric Lesion
Uehara, Y.
1153 - Introduction of the Kit Mutation into Immunodeficient Mice Enables Xenogeneic Reconstitution of Human Megakaryocyte-Erythroid Hematopoietic System
Uemura, N.
2322 - Effects of Daily Aspirin on Cancer Incidence and Mortality in the Japanese
Uemura, T.
4304 - Enumeration of Peripheral Blood Hematopoietic Stem Cells Using Automated Hematology Analyzer, Sysmex-XN: Final Resutls of Multicenter Prospective Study
Uemura, Y.
3424 - Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation
Ueno, H.
1022 - Whole-Exome Analysis of Autoimmune Lymphoproliferative Syndrome-like Diseases
1425 - Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
2687 - Genetic Basis of Primary Central Nervous System Lymphoma
Ueno, N.
2957 - PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells
Ueno, S.
2957 - PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells
Ueyama, J. I.
3724 - Augmented Consolidation Therapy Based on Minimal Residual Disease (MRD) and Analysis of the Measurement of Sequential MRD in Childhood Acute Lymphoblastic Leukemia : Children's Cancer and Leukemia Study Group of JAPAN (CCLSG), Cclsg ALL 2004 Protocol Study
Uger, R. A.
2191 - SIRPαFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction
Uggla, B.
3748 - Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry
Ugo, V.
2808 - Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up
Uguen, M.
1733 - Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia
Uhel, F.
1478 - T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12
Uhl, L.
2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
3471 - Therapeutic Plasma Exchange for the Treatment of Thrombotic Microangiopathy without Severe ADAMTS13 Deficiency: A Propensity Score-Matched Study
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease
Uhlar, C.
29 - Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
1829 - Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
3571 - Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab
Uhm, J.
1917 - Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation
1921 - Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion
1945 - Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis
1948 - Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen
3126 - Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease
3139 - Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd
3289 - Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation
Uhm, J.
2919 - Central Nervous System Involvement By Chronic Lymphocytic Leukemia
Uike, N.
2868 - A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)
Uike, N.
2714 - Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
Uitdehaag, J. C.
869 - 3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That Result in Constitutive JAK Kinase Activity
Ujjani, C. S.
471 - Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)
719 - Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
Ukaegbu, O. C.
1841 - Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis
Ukrainskyj, S. M.
452 - CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Ulintz, P.
2909 - A Quantitative Analysis of Subclonal and Clonal Gene Mutations Occurring Pre- and Post-Therapy in 53 Cases of Chronic Lymphocytic Leukemia
Ulirsch, J. C.
272 - Biallelic Mutations in PARP4 Are Linked to a Variant Form of Congenital Dyserythropoietic Anemia
1170 - Temporally Distinct Developmental Waves of Erythropoiesis from Human Pluripotent Stem Cells
Ullrich, J. G.
2799 - Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis
Ullrich, N.
3495 - Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in
Ulrich, B.
1240 - Mircrorna-550 Functions As a Critical Tumor Suppressor in Acute Myeloid Leukemia
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides
Ulrich, M.
330 - SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML
Ulrich, R. G.
2920 - The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
Ulrich, R. G.
2908 - ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity
Ulsh, P. J.
3459 - Congenital Thrombotic Thrombocytopenia Purpura - Safer Treatment with Plasma-Derived Viral-Attenuated Clotting Factor
Umaña, P.
2998 - A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys
Umapathy, N. S.
969 - Therapeutic Potential of Beta-Nicotinamide Adenine Dinucleotide to Reverse Endothelial Barrier Dysfunction in Sickle Cell Mouse Model
Umemura, K.
3147 - A Serum Biomarker Panel Composed of C-Reactive Protein and Albumin Could Predict the Transplant-Related Complications and the Outcomes of Allogeneic Hematopoietic Cell Transplantation
Umezawa, Y.
1270 - FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression
Ünalan, M.
2206 - Nicotinamidephosphoribosyltransferase (NAMPT) Induces Ubiquitination of LEF-1 Transcription Factor By Deacetylation
Underhill, C.
4236 - Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials
Ung, R.
3379 - Point-of-Care Screening for Sickle Cell Disease By a Mobile Micro-Electrophoresis Platform
Unger, M.
3567 - International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing
Unger, R.
3211 - A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT
Ungerstedt, J.
2398 - Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia
2834 - Histone Deacetylase Inhibitor SAHA Mediates Epigenetic Silencing of KIT D816V Mutated Systemic Mastocytosis Primary Mast Cells and Selective Apoptosis of Mutated Mast Cells
2839 - Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy
Ungureanu, C.
2823 - Assessment of Sites of Marrow and Extramedullary Hematopoieis By Hybrid Imaging in Patients with Primary Myelofibrosis
Unniachan, S.
2327 - Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom
Unnikrishnan, A.
710 - An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML
Uno, M.
2680 - A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Uno, T.
2800 - A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
Unterhalt, M.
333 - A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy
Uoshima, N.
3877 - The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
4182 - The Epigenetic Repression of Mir-375 Is the Dominant Mechanism for the Constitutive Activation of PDPK1/RSK2 Signaling Axis in Multiple Myeloma
Upadhyay, G.
2385 - Regulation of Erythro-Megakaryocytic Lineage Divergence By the Transcriptional Repressor Gfi1b and Its Rgs Targets
Uppal, G.
3892 - Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling
Uppenkamp, M. J.
2008 - Pretransplant NPM1-MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia
Urak, R.
930 - Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
3086 - Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy
Uran, T.
3332 - Tibetan Gain-of-Function Variant of Prolyl Hydroxylase 2 (EGLN1) and Selected SNPs of HIF-2-Alpha (EPAS1) Are Associated with Lower Hemoglobin Values in Tibetans
Urayama, K. Y.
3731 - Genetic Susceptibility Loci for Childhood Acute Lymphoblastic Leukemia Among Japanese
Urbano-Ispizua, A.
1787 - Cell-Cell Communication Between Multiple Myeloma (MM) Cells and Cord Blood Derived NK Cells (CB-NK) Regulates Both Tumor Cell Death and Tumor Cell Survival
3340 - Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry
Urbano-Ispizua, A.
3341 - Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients
4395 - Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution
Urbano-Ispizúa, Á.
3209 - Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis
Urbano-Izpizua, Á.
921 - A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell
Urbonya, R.
2187 - Hydroxyurea Shows Clinical Benefit without Alteration of Fetal Hemoglobin, MCV, or Hemoglobin in Unselected Adult and Pediatric Patients with Sickle Cell Anemia
Uribe, R.
4223 - Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)
Urity, V.
4359 - Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant
Urlaub, H.
2922 - Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment
Urlaub, H.
2453 - Phosphoproteomic Profiling of the Signaling Output of FLT3-ITD and Its AC220-Resistant Mutants Reveals Profound Signaling Differences and Differential Responsiveness to Inhibition of Downstream Kinases
Urnov, F. D.
203 - Genome Editing of the Bcl11A Erythroid Specific Enhancer in Bone Marrow Derived Hematopoietic Stem and Progenitor Cells for the Treatment of Sickle Cell Disease
204 - Clinical-Scale Genome Editing of the Human BCL11A Erythroid Enhancer for Treatment of the Hemoglobinopathies
3234 - Clonal Analysis of Human Bone Marrow CD34+ Cells Edited By BCL11A-Targeting Zinc Finger Nucleases Reveals Clinically Relevant Levels of Fetal Globin Expression in Edited Erythroid Progeny
Usai, C.
2410 - Shwachman-Diamond Syndrome: Energetic Stress, Calcium Homeostasis and mTOR Pathway
Usala, E.
1570 - Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
2792 - Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis
Usmani, S.
377 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
Usmani, S.
29 - Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
378 - Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)
728 - Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)
1829 - Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
3294 - Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)
4498 - Analyses of Real World Data on Overall Survival in Multiple Myeloma Patients with at Least 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD
Usmani, S. Z.
2966 - Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma
4183 - Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma
4440 - Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines
Usmani, S.
1279 - In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib
Ussowicz, M.
299 - Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
1662 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
Ustun, C.
321 - Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study
388 - Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients
1957 - ‘First-in-human’ phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy
4375 - Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment
Usui, N.
79 - Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O
4035 - Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
Usui, Y.
1690 - Clinical Significance of Bone Marrow Imaging of Appendicular Skeletons By Low-Dose Multi-Detector Computed Tomography in Patients with Bone Marrow Failure Syndrome
3056 - Reversal of Renal Function and Its Prognostic Impact in Patients with Multiple Myeloma in the Era of Novel Agents
3915 - Utility of Interim and Post-Therapy PET/CT in T-Cell and NK-Cell Lymphoma: A Single Institutional Analysis over 9 Years
Usuki, K.
1320 - ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
2024 - Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
4035 - Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
4371 - Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation
Uta, N.
3884 - Infiltration of Effector Regulatory T Cells Is Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Utley, A. T.
288 - CD28 Induces Mitochondrial Respiration through Slp-76 in Long-Lived Plasma Cells for Reactive Oxygen Species-Dependent Survival
Utsugisawa, T.
934 - COL4A1 is a Novel Causative Gene Responsible for Congenital Hemolytic Anemia, Representing Characteristic Clinical Course in Infants
2131 - ATP11C Encodes a Major Flippase in Human Erythrocyte and Its Genetic Defect Causes Congenital Non-Spherocytic Hemolytic Anemia
Utsunomiya, A.
572 - Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population
2703 - Mogamulizumab Therapy for Adult T-Cell Leukemia-Lymphoma: A Retrospective Multicenter Study
Uwamahoro, M. J.
2153 - Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study
Uy, G. L.
1935 - A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results
Uy, G. L.
319 - Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)
610 - Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
689 - Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients
796 - Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60
1686 - A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
1950 - Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes
2546 - The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
2793 - Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale
3098 - CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant
3106 - T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy
3144 - Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
Uygun, V.
959 - Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with Beta-Thalassemia Major
Uyttebroeck, A.
793 - t(12;21)/ETV6-RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group
1409 - Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia
2506 - Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01
3654 - ALK-Positive Anaplastic Large Cell Lymphoma with the Variant EEF1G-, RNF213- and Atic-ALK Fusions Is Featured By Copy Number Gain of the Rearranged ALK Gene
Uzel, G.
2229 - Haploidentical Transplantation for DOCK8 Deficiency
Uzunov, M.
492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia
3161 - Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring
4393 - Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z